Corr-4a

CFTR corrector

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

Corr-4a is an experimental substance from the Cystic Fibrosis Foundation Therapeutics library used in studies and not yet available as a human pharmaceutical. In relation to cystic fibrosis, our AIM tool found the data that corr-4a can help correct F508del-CFTR by stabilizing its structure.

Corr-4a on PubChem

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

Structure not available

C21H17ClN4O2S2

Drug-Mutation Relation

results for 120del23 / F508del
See all data on Corr-4a

Treats

Mutation Link Tested on Impact factor Notes
F508del Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis human cell cultures 2.81 Minimal effect on its own, better in combination with lumacaftor and ivacaftor.
F508del Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain. human cell cultures 8.25
F508del High-content Functional Screen to Identify Proteins that Correct F508del-CFTR Function*S⃞ human cell cultures 7.52
F508del RESCUE OF THE MUTANT CFTR CHLORIDE CHANNEL BY PHARMACOLOGICAL CORRECTORS AND LOW TEMPERATURE ANALYZED BY GENE EXPRESSION PROFILING human cell cultures 3.54

Does not treat

Mutation Link Tested on Impact factor Notes